(Q38446888)

3 September 2017

title

Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study (English)

1 reference

3 September 2017

1 reference

1 reference

2

Heidi Weiss

0 references

author name string

Syed K Mohsin

1

1 reference

3 September 2017

Thomas Havighurst

3

1 reference

3 September 2017

Gary M Clark

4

1 reference

3 September 2017

Melora Berardo

5

1 reference

3 September 2017

Le D Roanh

6

1 reference

3 September 2017

Ta V To

7

1 reference

3 September 2017

Zhang Qian

8

1 reference

3 September 2017

Richard R Love

9

1 reference

3 September 2017

D Craig Allred

10

1 reference

3 September 2017

publication date

1 December 2004

1 reference

3 September 2017

1 reference

3 September 2017

volume

17

1 reference

3 September 2017

issue

12

1 reference

3 September 2017

page(s)

1545-1554

1 reference

describes a project that uses

3 September 2017

1 reference

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Should immunohistochemical examination replace biochemical hormone receptor assays in breast cancer?

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Breast cancer prognostic factors: evaluation guidelines.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Comparison of different antibodies for detection of progesterone receptor in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Practical p-value adjustment for optimally selected cutpoints.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome [corrected]

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Immunocytochemical detection of progesterone receptor in breast cancer with monoclonal antibody. Relation to biochemical assay, disease-free survival, and clinical endocrine response

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Progesterone receptor determined by immunocytochemical and biochemical methods in human breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): prognostic usefulness and comparison with the biochemical radioactive-ligand-binding assay (DCC)

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

A prospective analysis of immunohistochemically determined hormone receptors and nuclear features as predictors of early recurrence in primary breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Estrogen and progesterone receptor status determined by the Ventana ES 320 automated immunohistochemical stainer and the CAS 200 image analyzer in 236 early-stage breast carcinomas: prognostic significance

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Progesterone receptors in routinely paraffin-embedded primary breast carcinomas and lymph node metastases

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800229

7 January 2021

10.1038/MODPATHOL.3800229

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

1025283936

0 references

1 reference